Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 0615-8313

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 0615-8313). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Donepezil HCl 10mg Tab 8313 Macleods 1)

Chemical structure diagram of Donepezil Hydrochloride, depicting its molecular framework including aromatic rings, piperidine ring, and associated functional groups.*

FDA Label Image

Fig-9 (Donepezil HCl 10mg Tab 8313 Macleods 10)

A line graph depicting the mean ADCS-ADL change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis shows clinical improvement and decline, while the x-axis represents months of treatment. Donepezil shows less clinical decline compared to placebo over time.*

FDA Label Image

Fig-10 (Donepezil HCl 10mg Tab 8313 Macleods 11)

A cumulative percentage of patients graph comparing Donepezil Hydrochloride 10 mg/day and placebo. The x-axis represents ADCS-ADL change from baseline (ranging approximately from +20 to -20), and the y-axis shows the cumulative percentage of patients (0% to 100%). The graph displays two curves, one with filled circles for Donepezil Hydrochloride 10 mg/day and one with open squares for placebo, illustrating the distribution of patient responses in terms of functional change.*

FDA Label Image

Fig-11 (Donepezil HCl 10mg Tab 8313 Macleods 12)

A line graph showing the mean change from baseline in SIB (Severe Impairment Battery) scores over 24 weeks of treatment for Donepezil Hydrochloride at 10 mg/day and 23 mg/day. The graph includes error bars, with clinical improvement above baseline and clinical decline below baseline indicated on the y-axis.*

FDA Label Image

Fig-12 (Donepezil HCl 10mg Tab 8313 Macleods 13)

A cumulative percentage of patients line graph comparing SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride at two doses: 10 mg/day and 23 mg/day. The x-axis shows SIB change from baseline, and the y-axis indicates cumulative percentage of patients, illustrating the distribution of patient responses for each dosage group.*

FDA Label Image

Fig-13 (Donepezil HCl 10mg Tab 8313 Macleods 14)

Bar graph comparing the percentage of patients by CIBIC-plus ratings for Donepezil Hydrochloride 10 mg/day and 23 mg/day. Ratings range from Markedly Improved to Markedly Worse, showing proportions of patients with no change, minimal improvement or worsening, and moderate or marked changes in condition.*

FDA Label Image

Donepezil 10mg Tab Bingo Card Label (Donepezil HCl 10mg Tab 8313 Macleods 15)

Donepezil Hydrochloride 10 mg film-coated tablets label showing packaging by NCS HealthCare of KY, LLC dba Vangard Labs. The label includes barcode, lot number 8313, and storage instructions to keep at 20°-25°C. The product is marked for institutional use only with multiple barcode strips for dispensing or inventory control, emphasizing the 10 mg strength and oral tablet dosage form.*

FDA Label Image

Fig-1 (Donepezil HCl 10mg Tab 8313 Macleods 2)

A line graph depicting the change from baseline in ADAS-cog scores over 24 weeks of treatment for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The vertical axis shows mean change (± SE), with negative values indicating clinical improvement and positive values indicating clinical decline. The horizontal axis represents the weeks of drug treatment. Donepezil groups show improvement, while placebo shows decline over time.*

FDA Label Image

Fig-2 (Donepezil HCl 10mg Tab 8313 Macleods 3)

A cumulative percentage of patients chart showing change from baseline on the x-axis and cumulative percentage of patients on the y-axis. It compares Donepezil Hydrochloride 10 mg and 5 mg doses against placebo, illustrating patient distribution over changes in ADAS-cognitive scale scores. Chart includes a legend and a small inset table summarizing percentage of patients at various score changes for each treatment group.*

FDA Label Image

Fig-3 (Donepezil HCl 10mg Tab 8313 Macleods 4)

Bar chart illustrating the distribution of CIBIC-plus ratings among patients treated with Donepezil Hydrochloride at doses of 10 mg/day and 5 mg/day, compared to a placebo group. The vertical axis represents the percentage of patients, and the horizontal axis lists ratings from Markedly Improved to Markedly Worse. Percentages vary across these categories for each treatment group.*

FDA Label Image

Fig-4 (Donepezil HCl 10mg Tab 8313 Macleods 5)

A line graph depicting ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) change from baseline (mean ± SE) over 15 weeks of drug treatment. It compares the effects of Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo on cognitive function. The y-axis shows change from baseline with clinical improvement and clinical decline indicated, while the x-axis shows weeks of treatment.*

FDA Label Image

Fig-5 (Donepezil HCl 10mg Tab 8313 Macleods 6)

A cumulative percentage graph illustrating changes from baseline in ADAS-cog scores among patients treated with Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. A table compares treatment groups with percentages of patients achieving specific changes (-7, -4, 0) in ADAS-cog scores.*

FDA Label Image

Fig-6 (Donepezil HCl 10mg Tab 8313 Macleods 7)

Bar chart depicting the percentage of patients rated by CIBIC-plus across categories from Markedly Improved to Markedly Worse. The chart compares Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups, showing distribution of patient outcomes by rating category.*

FDA Label Image

Fig-7 (Donepezil HCl 10mg Tab 8313 Macleods 8)

A line graph showing the mean change in SIB (Severe Impairment Battery) scores from baseline over 6 months of treatment. Two lines compare Donepezil Hydrochloride 10 mg/day versus placebo. The Donepezil group shows clinical improvement, peaking around 3 months and slightly decreasing by 6 months, while the placebo group shows clinical decline over time.*

FDA Label Image

Fig-8 (Donepezil HCl 10mg Tab 8313 Macleods 9)

A cumulative percentage chart showing SIB (Severe Impairment Battery) change from baseline on the x-axis and cumulative percentage of patients on the y-axis. Two curves represent Donepezil Hydrochloride 10 mg/day and placebo groups, illustrating the distribution of patient responses over a range of SIB score changes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.